



**JDRF INTERNATIONAL**

Consolidated Financial Statements

June 30, 2017 and 2016

(With Independent Auditors' Report Thereon)



KPMG LLP  
345 Park Avenue  
New York, NY 10154-0102

## Independent Auditors' Report

The Board of Directors  
JDRF International:

We have audited the accompanying consolidated financial statements of JDRF International, which comprise the consolidated statements of financial position as of June 30, 2017 and 2016, and the related consolidated statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

### Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

### Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of JDRF International as of June 30, 2017 and 2016, and the changes in its net assets and its cash flows for the years then ended, in accordance with U.S. generally accepted accounting principles.

**KPMG LLP**

October 26, 2017

**JDRF INTERNATIONAL**

## Consolidated Statements of Financial Position

June 30, 2017 and 2016

(In thousands)

<b>Assets</b>	<b>2017</b>	<b>2016</b>
Cash and cash equivalents	\$ 54,241	64,706
Investments (note 3):		
Financial investments	78,032	73,180
Programmatic investments	3,750	125
Contributions and other receivable, net (note 6)	42,418	41,013
Programmatic notes receivable (note 7)	3,500	—
Prepaid expenses and other assets	7,092	4,480
Fixed assets, net (note 8)	9,720	13,590
Total assets	<u>\$ 198,753</u>	<u>197,094</u>
<b>Liabilities and Net Assets</b>		
Liabilities:		
Accounts payable and accrued expenses	\$ 16,729	16,336
Research grants payable (note 10)	94,060	105,779
Deferred revenue	7,935	8,341
Liabilities related to split-interest agreements	2,661	2,743
Total liabilities	<u>121,385</u>	<u>133,199</u>
Commitments and contingencies (note 11)		
Net assets (note 12):		
Unrestricted	39,586	24,131
Temporarily restricted	30,441	32,690
Permanently restricted	7,341	7,074
Total net assets	<u>77,368</u>	<u>63,895</u>
Total liabilities and net assets	<u>\$ 198,753</u>	<u>197,094</u>

See accompanying notes to consolidated financial statements.

**JDRF INTERNATIONAL**  
Consolidated Statements of Activities  
Years ended June 30, 2017 and 2016  
(In thousands)

	2017				2016			
	Unrestricted	Temporarily restricted	Permanently restricted	Total	Unrestricted	Temporarily restricted	Permanently restricted	Total
Public support and revenue:								
Public support:								
Contributions	\$ 41,981	22,582	—	64,563	46,907	16,104	—	63,011
Events revenue:								
Proceeds	155,671	—	—	155,671	153,113	—	—	153,113
Direct donor benefits	(27,153)	—	—	(27,153)	(26,852)	—	—	(26,852)
Contributions from international affiliates (note 9)	7,662	—	—	7,662	8,439	—	—	8,439
Total public support	178,161	22,582	—	200,743	181,607	16,104	—	197,711
Revenue:								
Investment return (loss), net (note 3)	5,416	101	267	5,784	(426)	38	—	(388)
Other	283	—	—	283	119	—	—	119
Total revenue (loss)	5,699	101	267	6,067	(307)	38	—	(269)
Net assets released from restrictions	24,932	(24,932)	—	—	14,716	(14,716)	—	—
Total public support and revenue	208,792	(2,249)	267	206,810	196,016	1,426	—	197,442
Expenses:								
Program services:								
Research, net (note 10)	99,876	—	—	99,876	96,274	—	—	96,274
Public education and advocacy	52,764	—	—	52,764	52,292	—	—	52,292
Total program services	152,640	—	—	152,640	148,566	—	—	148,566
Supporting services:								
Management and general	14,933	—	—	14,933	14,837	—	—	14,837
Fundraising	25,764	—	—	25,764	25,624	—	—	25,624
Total supporting services	40,697	—	—	40,697	40,461	—	—	40,461
Total expenses	193,337	—	—	193,337	189,027	—	—	189,027
Change in net assets	15,455	(2,249)	267	13,473	6,989	1,426	—	8,415
Net assets at beginning of year	24,131	32,690	7,074	63,895	17,142	31,264	7,074	55,480
Net assets at end of year	\$ 39,586	30,441	7,341	77,368	24,131	32,690	7,074	63,895

See accompanying notes to consolidated financial statements.

**JDRF INTERNATIONAL**

Consolidated Statements of Functional Expenses

Years ended June 30, 2017 and 2016

(In thousands)

	2017						Total expenses
	Program services			Supporting services			
	Research	Public education and advocacy	Total	Management and general	Fundraising	Total	
Research grants, net (note 10)	\$ 79,009	—	79,009	—	—	—	79,009
Payroll and related expenses	13,735	34,555	48,290	9,917	17,140	27,057	75,347
Printing and promotional expenses	564	2,192	2,756	432	1,979	2,411	5,167
Occupancy	3,188	8,120	11,308	3,218	4,072	7,290	18,598
Meetings and conferences	1,168	2,504	3,672	487	952	1,439	5,111
Professional services	1,918	3,183	5,101	339	733	1,072	6,173
Miscellaneous	294	2,210	2,504	540	888	1,428	3,932
Total expenses	\$ 99,876	52,764	152,640	14,933	25,764	40,697	193,337
Costs of direct benefits to donors							27,153
Total expenses and costs of direct benefits to donors							\$ 220,490
	2016						Total expenses
	Program services			Supporting services			
	Research	Public education and advocacy	Total	Management and general	Fundraising	Total	
Research grants, net (note 10)	\$ 75,084	—	75,084	—	—	—	75,084
Payroll and related expenses	13,373	33,907	47,280	9,656	17,212	26,868	74,148
Printing and promotional expenses	420	1,904	2,324	403	1,669	2,072	4,396
Occupancy	3,521	8,380	11,901	3,401	4,236	7,637	19,538
Meetings and conferences	1,633	2,271	3,904	509	942	1,451	5,355
Professional services	2,056	3,661	5,717	341	705	1,046	6,763
Miscellaneous	187	2,169	2,356	527	860	1,387	3,743
Total expenses	\$ 96,274	52,292	148,566	14,837	25,624	40,461	189,027
Costs of direct benefits to donors							26,852
Total expenses and costs of direct benefits to donors							\$ 215,879

See accompanying notes to consolidated financial statements.

**JDRF INTERNATIONAL**

Consolidated Statements of Cash Flows

Years ended June 30, 2017 and 2016

(In thousands)

	<u>2017</u>	<u>2016</u>
Cash flows from operating activities:		
Change in net assets	\$ 13,473	8,415
Adjustments to reconcile change in net assets to net cash (used in) provided by operating activities:		
Net (appreciation) depreciation in fair value of investments	(5,642)	497
Depreciation and amortization	4,631	4,177
Deferred rent credits	(350)	(244)
Changes in operating assets and liabilities:		
Contributions and other receivables	(1,405)	(1,125)
Prepaid expenses and other assets	(2,612)	(696)
Accounts payable and accrued expenses	743	2,688
Research grants payable	(11,719)	619
Deferred revenue	(406)	1,650
Liabilities related to split-interest agreements	(82)	(75)
Net cash (used in) provided by operating activities	<u>(3,369)</u>	<u>15,906</u>
Cash flows from investing activities:		
Purchase of fixed assets	(761)	(1,293)
Funding of programmatic investments	(3,625)	(125)
Disbursement of programmatic notes	(3,500)	—
Purchase of investments	(227)	(564)
Proceeds from sale of investments	1,017	13,067
Net cash (used in) provided by investing activities	<u>(7,096)</u>	<u>11,085</u>
Change in cash and cash equivalents	(10,465)	26,991
Cash and cash equivalents at beginning of year	<u>64,706</u>	<u>37,715</u>
Cash and cash equivalents at end of year	\$ <u>54,241</u>	\$ <u>64,706</u>

See accompanying notes to consolidated financial statements.

## JDRF INTERNATIONAL

### Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(In thousands)

#### (1) Organization

JDRF International (JDRF) is the leading global nonprofit organization funding type 1 diabetes (T1D) research with a mission to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. Guided by a strategic plan, JDRF maintains an in-house team of experts that identifies the most promising research to fulfill its mission. Over the decades, JDRF's work has resulted in significant developments in the understanding of the disease—bringing us closer to prevention and a cure—and better treatment options for people with T1D.

In addition to direct research funding, JDRF is able to leverage its influence to attract hundreds of millions of dollars more in follow-on investments by third parties to the T1D space each year by third parties. JDRF's ability to create funding partnerships and attract follow-on funding is a direct reflection of the credibility, success and influence that has been established over nearly five decades. By leveraging relationships, JDRF helps generate a greater number of innovative approaches to curing, preventing and better treating T1D.

JDRF solicits contributions from the public and engages in various fundraising activities. Funds raised are used principally to support T1D research. Furthermore, JDRF promotes public education initiatives and advocates for U.S. and foreign government funding of T1D research and raises awareness among Members of Congress of the financial, medical and emotional costs of the disease.

Since 1997, JDRF has helped secure nearly \$2.5 billion in Federal funding for T1D research through the Special Diabetes Program. This program—administered by the National Institutes of Health—has produced tangible results in advancing cure therapies, prevention studies and treatments—including artificial pancreas technology and groundbreaking advances in vision improvement among people with diabetic eye disease. JDRF also advocates for regulatory and health policies, which enable research to proceed without delay and provide widespread access to life-changing T1D therapies.

JDRF drives early stage commercial investment in T1D therapies through an independently managed venture philanthropy fund. JDRF T1D Fund LLC (The Fund), formerly JDRF Therapeutics Fund LLC, is a limited liability company whose sole member is JDRF and was activated during the year ended June 30, 2016, and is considered a disregarded entity of JDRF. The purpose of The Fund is to materially accelerate the development of drugs, devices, diagnostics, and vaccines to treat, prevent and cure T1D. The Fund provides funding to companies and institutions conducting such T1D research and development through investment capital or other commercial agreements using donations made to The Fund and monies provided by JDRF.

JDRF financial results are presented on a consolidated basis, including JDRF and The Fund. All significant inter-company balances and transactions have been eliminated in consolidation.

JDRF's consolidated financial statements include the accounts of The Fund and JDRF Chapters located throughout the United States. International affiliates are located in Canada, Australia, the United Kingdom, and a number of other countries. The financial statements of these international affiliates are not included in the accompanying consolidated financial statements since JDRF does not exercise control over their management or operations. However, international affiliates do provide contributions to JDRF to support funding of research grants as presented in note 9.

## JDRF INTERNATIONAL

### Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(In thousands)

JDRF is a not-for-profit organization exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code and is organized under the laws of the Commonwealth of Pennsylvania. The effect of income tax positions is recognized only if those positions are more likely than not of being sustained. Income generated from activities unrelated to JDRF's exempt purpose is subject to tax under Internal Revenue Code Section 511. Unrelated business income tax liability was insignificant for the years ended June 30, 2017 and 2016.

## (2) Summary of Significant Accounting Policies

### (a) Basis of Presentation

JDRF's consolidated financial statements are prepared on the accrual basis of accounting in accordance with standards established by the Financial Accounting Standards Board (FASB) for external financial reporting by not-for-profit organizations. Accordingly, net assets and changes therein are classified and reported as follows:

*Unrestricted Net Assets* – Net assets that are not subject to donor-imposed restrictions.

*Temporarily Restricted Net Assets* – Net assets subject to donor-imposed restrictions that will be met either by actions of JDRF or by the passage of time.

*Permanently Restricted Net Assets* – Net assets subject to donor-imposed restrictions, that stipulate that the principal be maintained permanently, but permit JDRF to expend part or all of the income and gains derived therefrom.

Revenues and gains and losses on investments and other assets are reported as changes in unrestricted net assets unless limited by explicit donor-imposed restrictions or by law. Expenses are reported as decreases in unrestricted net assets.

When a time restriction ends or a purpose restriction is accomplished, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statements of activities as net assets released from restrictions.

### (b) Contributions

Contributions, including unconditional promises to give (pledges), are reported as revenues in the period received or pledged. Contributions with purpose or time restrictions are reported as increases in temporarily restricted net assets and are reclassified to unrestricted net assets when the purpose or time restrictions are met. Contributions subject to donor-imposed stipulations that the corpus be maintained permanently are recognized as increases in permanently restricted net assets.

Unconditional promises to give are recognized initially at fair value as contributions revenue in the period such promises are made by donors. Fair value is estimated giving consideration to anticipated future cash receipts (after allowance is made for uncollectible contributions) and discounting such amounts at a treasury yield rate commensurate with the duration of the donor's payment plan. In subsequent periods, the discount rate is unchanged and the allowance for uncollectible contributions is reassessed and adjusted if necessary. Amortization of the discounts is recorded as additional contribution revenue.



## **JDRF INTERNATIONAL**

### Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(In thousands)

Conditional promises to give are not recognized until they become unconditional, that is, when the conditions on which they depend are substantially met. Contributions of assets other than cash are recorded at their estimated fair value. Contributions expected to be received after one year are discounted at a treasury yield rate of return. Amortization of the discount is recorded as additional contribution revenue in accordance with the donor-imposed restrictions, if any, on the contribution.

Contributions received for future events, primarily walk and ride events, are recorded as deferred revenue and are recognized as revenue in the fiscal year the event takes place, which is generally within one year.

JDRF administers two types of split-interest agreements – Charitable Gift Annuities and Charitable Remainder Trusts. With Charitable Gift Annuities, cash or marketable securities are received from a donor in exchange for an annuity to be distributed for a fixed amount over the lifetime or lifetimes of the donor or other beneficiaries. With Charitable Remainder Trusts administered by JDRF, donated assets are received under a trust agreement established by the donor in exchange for an income stream to be distributed to the donor and/or other beneficiaries over a specified period of time. The distribution to the donor or other beneficiaries may be a fixed dollar amount (an annuity trust) or percentage of the fair value of the trust as determined annually (unitrust). For both Charitable Gift Annuities and Charitable Remainder Trusts, a related liability is recorded for the actuarially determined present value of the obligation to the annuitant or annuitants. The discount rates used to calculate the liability range between 1.2% and 8.2% at June 30, 2017. For Charitable Gift Annuities, the assets received are held by JDRF as general assets and the annuity liability is a general obligation.

#### **(c) Cash and Cash Equivalents**

Cash equivalents consist of money market accounts, demand notes, savings accounts, and certificates of deposit purchased with original maturities of three months or less, except for such instruments purchased by JDRF's investment managers as part of their investment strategies.

#### **(d) Investments**

Investments include (i) Financial Investments made to increase earnings for support of JDRF's mission and investments which support underlying planned giving and endowment agreements and (ii) Programmatic Investments made to provide equity capital to companies to materially accelerate the development of drugs, devices, diagnostics, and vaccines to treat, prevent and cure T1D.

Financial Investments in debt and equity securities, including assets related to split-interest agreements, with readily determinable fair values are reported at fair value based upon quoted market prices. Investments in funds, which report net asset value (NAV) or its equivalent (NAV funds), are reported at estimated fair value. The estimated fair value of NAV funds, as a practical expedient, is the net asset value as provided by the investment managers, and evaluated for reasonableness by JDRF. Due to the inherent uncertainties of these estimates, these values may differ from the values that would have been used had a ready market existed for such investments.

Programmatic Investments in equity securities are recorded at the lower of cost or fair market value which is evaluated annually.

## JDRF INTERNATIONAL

### Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(In thousands)

#### **(e) Fixed Assets**

Fixed assets, which consist of furniture, equipment, and leasehold improvements, are recorded at cost. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets, which approximate 3 to 10 years for furniture and equipment. Leasehold improvements are amortized on a straight-line basis over the shorter of the life of the asset or the lease term.

#### **(f) Fair Value**

Assets and liabilities reported at fair value are required to be classified within a fair value hierarchy, which gives preference to the use of observable inputs over unobservable inputs. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of the fair value hierarchy are as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.
- Level 2 inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 inputs are unobservable inputs used when little or no market data is available.

JDRF follows Accounting Standards Update (ASU) No. 2015-07, *Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or its Equivalent)*, which removes the requirements to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient and removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient.

#### **(g) Functional Allocation of Expenses**

The costs of providing the various programs and other activities have been summarized on a functional basis. Accordingly, certain costs have been allocated among the programs and supporting services areas that were benefited.

#### **(h) Allocation of Joint Costs**

JDRF allocates joint costs between fund-raising and program services or management and general in accordance with Accounting Standards Codification Subtopic (ASC) No. 958-720, *Accounting for Costs of Activities of Not-for-Profit Organizations and State and Local Governmental Entities That Include Fundraising*.

## JDRF INTERNATIONAL

### Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(In thousands)

#### (i) Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingencies at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the year. Significant estimates made in the preparation of the consolidated financial statements include fair value of investments in NAV funds, net realizable value of contributions receivable, and functional expense allocation. Actual results could differ from those estimates.

#### (j) Reclassification

Certain prior year amounts have been reclassified to conform with the current year presentation.

### (3) Investments

Investments (including Programmatic Investments) at June 30, 2017 and 2016 consisted of the following:

	<u>2017</u>	<u>2016</u>
Investments measured at Fair Value (Level 1):		
Cash and cash equivalents	\$ 38	105
Mutual funds:		
Equity, principally domestic	16,248	14,953
Fixed income, principally government	21,964	21,882
Investments measured at NAV:		
Fixed income funds	4,122	4,181
Global equity funds	10,214	8,244
Real assets funds	3,054	2,928
Hedge funds	22,392	20,887
Investments measured at cost:		
Preferred stock	3,750	125
Total investments	<u>\$ 81,782</u>	<u>73,305</u>

Included in investments are amounts related to Charitable Gift Annuities and Charitable Remainder Trusts totaling \$2,576 and \$1,608, respectively, at June 30, 2017 and \$2,478 and \$2,454, respectively, at June 30, 2016.

Investments are exposed to various risks, such as market and credit risks. Because of such risks, it is possible that change in investment values will occur and that such changes could materially affect JDRF's consolidated financial statements.

## JDRF INTERNATIONAL

### Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(In thousands)

**Preferred stock** – During fiscal year 2017, the Fund made investments in three private companies for which it holds Series A Preferred Stock to provide equity capital to help materially accelerate the development of drugs, devices, diagnostics, and vaccines to treat, prevent and cure T1D. These Programmatic Investments are reported at cost as of June 30, 2017. As of June 30, 2017, unfunded contingent commitments to certain programmatic investments are \$250.

Information with respect to the strategies of investments measured at NAV is as follows:

**Fixed income funds** – Investments in one fund that invests in sovereign bonds – both in the United States and globally, as well as bank loans.

**Global equity funds** – Investments in one fund that seeks to benefit from the compounding effect of accumulated earnings, assets, and dividends of the portfolio’s underlying companies. Investments are in long positions, predominately in developed and emerging markets outside of the United States.

**Real assets funds** – Investments in one fund that invests in liquid energy, real estate, and natural resources equities, as well as commodities and TIPS.

**Hedge funds** – Investments in three funds that employ “alternative” strategies, primarily involving marketable securities. In addition to stocks and bonds, financial instruments traded by these funds may include derivatives contracts (e.g., futures, forwards, swaps, and options related to stocks, bonds, commodities, interest rates, or currencies), or less liquid assets such as private placements, structured products, bank loans, real estate, and special-purpose vehicles. These funds often employ the use of leverage and short selling.

The limitations and restrictions on JDRF’s ability to redeem or sell its investments in NAV funds vary by investment. Based upon the terms and conditions in effect at June 30, 2017, these investments in NAV funds can be redeemed or sold as follows:

	<u>Amounts</u>
Less than a month	\$ —
Monthly	17,390
Quarterly	13,930
Annually (calendar basis and investment anniversary)	<u>8,462</u>
	<u>\$ 39,782</u>

There were no unfunded commitments as of June 30, 2017.

**JDRF INTERNATIONAL**

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(In thousands)

The components of investment return and its classification in the consolidated statements of activities for the years ended June 30, 2017 and 2016 were as follows:

		<b>2017</b>			
		<b>Unrestricted</b>	<b>Temporarily restricted</b>	<b>Permanently restricted</b>	<b>Total</b>
Interest and dividends, net	\$	129	—	13	142
Net appreciation		5,287	101	254	5,642
	\$	<u>5,416</u>	<u>101</u>	<u>267</u>	<u>5,784</u>

  

		<b>2016</b>			
		<b>Unrestricted</b>	<b>Temporarily restricted</b>	<b>Permanently restricted</b>	<b>Total</b>
Interest and dividends, net	\$	47	50	12	109
Net appreciation		(473)	(12)	(12)	(497)
	\$	<u>(426)</u>	<u>38</u>	<u>—</u>	<u>(388)</u>

Investment expenses relating to investment advisors, managers, and custodians and other bank charges are recorded as reductions to interest and dividend income. Investment expenses paid directly totaled \$452 for the years ended June 30, 2017 and 2016.

**(4) Retirement Plans**

JDRF maintains a Tax Deferred Annuity Plan (403B) which allows employees to defer a portion of their wages for saving for retirement. This Plan was amended effective July 1, 2015 to provide an annual employer matching contribution equal to 100% of an employee's own contributions for the first 3% of annual eligible wages and 50% of the next 3% for a maximum possible contribution match of 4.5% of annual eligible earnings. To receive employer matching contributions, an eligible employee must be employed by JDRF on the last day of the Plan year. Related contribution expense for the year ended June 30, 2017 was \$1,468.

JDRF also maintains a 401A Retirement Plan which was previously used by the JDRF to support employee retirement savings through a discretionary annual contribution to eligible employees. JDRF has redirected the majority of its support for employee retirement savings to the 403B Plan but continued to maintain the 401A Plan with reduced contribution funding throughout the 2017 fiscal year. Related contributions expense to the 401A Plan for the years ended June 30, 2017 and 2016 was \$50 and \$51, respectively. The 401A Retirement Plan was terminated on June 30, 2017.

**JDRF INTERNATIONAL**

## Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(In thousands)

**(5) Allocation of Joint Costs**

In 2017 and 2016, JDRF conducted activities, principally direct mail, that included fundraising appeals as well as program components. The joint costs incurred were allocated as follows:

	<u>2017</u>	<u>2016</u>
Public education	\$ 743	756
Management and general	112	128
Fundraising	<u>1,250</u>	<u>1,211</u>
Total	<u>\$ 2,105</u>	<u>2,095</u>

**(6) Contributions Receivable**

Contributions receivable include pledges due in future periods, uncollected events revenues, and affiliate contributions receivable.

Contributions and other receivables at June 30, 2017 and 2016 consisted of the following:

	<u>2017</u>	<u>2016</u>
Gross pledges receivable, due in:		
Less than one year	\$ 14,288	9,618
One to five years	15,684	17,872
Thereafter	<u>20</u>	<u>40</u>
	29,992	27,530
Less:		
Allowance for doubtful accounts	(1,443)	(1,753)
Unamortized discount to present value, at rates ranging from 0.28% to 5.1%	<u>(406)</u>	<u>(362)</u>
Pledges receivable, net	28,143	25,415
Other contributions receivable	9,847	10,504
Events revenues receivables	<u>4,428</u>	<u>5,094</u>
	<u>\$ 42,418</u>	<u>41,013</u>

At June 30, 2017 and 2016, the ten largest contributions receivable represented 24% and 31% of the total outstanding contributions and other receivables respectively.

**(7) Programmatic Notes Receivable**

Programmatic notes receivable represent loans made to companies to provide capital to materially accelerate the development of drugs, devices, diagnostics, and vaccines to treat, prevent, and cure T1D.

## JDRF INTERNATIONAL

### Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(In thousands)

During fiscal year 2017, the Fund entered into two convertible promissory notes with private companies. These promissory notes bear interest and are convertible into shares of the company's preferred stock under certain conditions. The notes receivable are recorded at net realizable value at June 30, 2017.

#### (8) Fixed Assets

Fixed assets at June 30, 2017 and 2016 consisted of the following:

	<u>2017</u>	<u>2016</u>
Furniture and equipment	\$ 26,514	25,754
Leasehold improvements	4,723	4,722
	31,237	30,476
Less accumulated depreciation and amortization	(21,517)	(16,886)
Fixed assets, net	<u>\$ 9,720</u>	<u>13,590</u>

#### (9) Contributions from International Affiliates

During the years ended June 30, 2017 and 2016, JDRF received contributions from affiliates as follows:

	<u>2017</u>	<u>2016</u>
JDRF – Canada	\$ 3,801	3,837
JDRF – United Kingdom	2,150	2,516
JDRF – Australia	1,540	1,735
JDRF – Netherlands	146	250
JDRF – Denmark	—	71
JDRF – Israel	25	30
	<u>\$ 7,662</u>	<u>8,439</u>

In April 2015, JDRF and the Affiliates reached an agreement on a renewed three-year Affiliate Agreement with an option for a three year renewal, with all agreements to expire in 2021. The Agreement remains much the same as the previous agreement but with the addition of a provision for termination with and termination without cause.

**JDRF INTERNATIONAL**

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(In thousands)

**(10) Research Grants Payable**

Research grants payable at June 30, 2017 and 2016 consisted of the following:

	<u>2017</u>	<u>2016</u>
Amounts expected to be paid in:		
Less than one year	\$ 78,882	92,150
One to five years	<u>15,368</u>	<u>13,695</u>
Subtotal	94,250	105,845
Less discount to present value, at rates ranging from 0.28% to 1.24%	<u>(190)</u>	<u>(66)</u>
Total	<u>\$ 94,060</u>	<u>105,779</u>

Research grant expense is net of any grant refunds, reductions, or terminations. These adjustments were \$5,289 and \$8,891 for the years ended June 30, 2017 and 2016, respectively.

**(11) Commitments and Contingencies**

**(a) Research Grants**

As of June 30, 2017, JDRF's conditional research grants commitments, including milestone contracts, of \$82,300, which will be recognized in the consolidated financial statements when the conditions have been substantially met, are currently estimated to be payable as follows:

2018	\$ 43,800
2019	33,700
2020	3,600
2021	1,000
2022	<u>200</u>
	<u>\$ 82,300</u>

**(b) Leases**

JDRF is obligated under various leases for space occupied by certain chapters. Rent expense, including maintenance costs for the chapters, was \$4,079 and \$4,173 for the years ended June 30, 2017 and 2016, respectively.



**JDRF INTERNATIONAL**

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(In thousands)

Rental commitments for all leases are as follows:

2018	\$	7,009
2019		5,714
2020		3,655
2021		1,512
2022		1,963
	\$	<u>19,853</u>

Rent expense is recognized on a straight-line basis, and accordingly, a deferred rent credit has been recorded. At June 30, 2017 and 2016, a credit of approximately \$1,372 and \$1,722, respectively, is included in accounts payable and accrued expenses.

**(c) Line of Credit**

On January 23, 2013, JDRF entered into an agreement with a financial institution for an unsecured line of credit in the aggregate amount of \$5 million. The line of credit expires December 31, 2017. The line was not used in fiscal year 2017 and 2016 and no amounts outstanding at June 30, 2017 or 2016.

**(12) Net Assets**

**(a) Temporarily Restricted Net Assets**

At June 30, 2017 and 2016, temporarily restricted net assets were available for the following purposes:

	<u>2017</u>	<u>2016</u>
Future periods, principally pledges receivable and split-interest agreements	\$ 28,834	26,913
Other contributions/purpose restricted	<u>1,607</u>	<u>5,777</u>
	<u>\$ 30,441</u>	<u>32,690</u>

**JDRF INTERNATIONAL**

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(In thousands)

**(b) Permanently Restricted Net Assets**

At June 30, 2017 and 2016, the investment return derived from permanently restricted net assets was expendable to support:

	<b>2017</b>	<b>2016</b>
General activities	\$ 2,936	2,902
Research projects:		
Artificial pancreas project	2,000	2,000
Virginia Mason Research Center	2,405	2,172
	<b>\$ 7,341</b>	<b>7,074</b>

**(c) Endowment**

JDRF's endowment consists of six individual donor-restricted endowment funds established for a variety of purposes. The Commonwealth of Pennsylvania has not enacted a version of the Uniform Prudent Management of Institutional Funds Act (UPMIFA), or a version of the Uniform Management of Institutional Funds Act (UMIFA). Governing law resides in 15 Pa. C.S. § 5548, *Investment of Trust Funds*. JDRF has interpreted Pennsylvania law as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, permanently restricted net assets include (a) the original value of gifts to the permanent endowment and (b) accumulations of investment returns to the permanent endowment made in accordance with the direction of the applicable donor gift instrument, when applicable. The endowment funds are invested in SEC registered, institutional quality mutual funds across a range of diversified asset classes including domestic and international large and small cap stocks, emerging markets equities, domestic and international REITs, domestic and foreign bonds, and investment grade and high yield bonds.

The following tables present the changes in donor-restricted endowment funds:

		<b>2017</b>		
		<b>Temporarily restricted</b>	<b>Permanently restricted</b>	<b>Total</b>
Endowment net assets at June 30, 2016	\$	102	7,074	7,176
Investment income		—	13	13
Net appreciation		101	254	355
Appropriation for expenditure		(102)	—	(102)
Endowment net assets at June 30, 2017	\$	101	7,341	7,442

**JDRF INTERNATIONAL**

## Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(In thousands)

	<b>2016</b>		
	<b>Temporarily restricted</b>	<b>Permanently restricted</b>	<b>Total</b>
Endowment net assets at June 30, 2015	\$ 67	7,074	7,141
Investment income	50	12	62
Net appreciation	(12)	(12)	(24)
Appropriation for expenditure	(3)	—	(3)
Endowment net assets at June 30, 2016	\$ <u>102</u>	<u>7,074</u>	<u>7,176</u>

**(13) Subsequent Events**

In connection with the preparation of the consolidated financial statements, JDRF evaluated subsequent events after the consolidated statement of financial position date of June 30, 2017 through October 26, 2017, the date the consolidated financial statements were available for issuance. JDRF has determined that there are no subsequent events to disclose.